Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
New York: below-average open trial sites
3,675 of 10,554 in-state trials are recruiting (35%); below the 37% national average by 2 percentage points, with Phase 2 weight.
According to ClinicalTrials.gov-derived indexes, New York sits in the top decile of US states by in-state trial count (#3 of 52 states by registered in-state trial count).
New York: 10,554 US clinical trials with in-state sites, 3,675 recruiting.
New York has 10,554 registered US clinical trials with a study site in-state, 3,675 of them currently recruiting (below the 37% national average by 2 percentage points). 1,424 of these trials are in Phase 3 (late-stage) and 2,430 in Phase 2. The most frequently studied condition in New York is Breast Cancer, with 270 linked trials.
Peer research-density states
New York is in the top decile by in-state trial count. Nearest hubs by indexed volume (not open-share twins):
- Florida (10,986)
- Texas (9,951)
- Massachusetts (7,667)
- Pennsylvania (6,946)
- Illinois (6,854)
Ranked from 51 other states with active in-state trials by how close each state's indexed trial count sits to New York's.
Below-average open, early-phase tilt
New York still shows 3,675 recruiting of 10,554 in-state trials (35% open), but below the 37% national average by 2 percentage points, so archived statuses weigh heavier than the national baseline.
- 35%
- open (below national share)
- 3,675
- still recruiting despite cool share
- 2,430
- Phase 2 rows in this footprint
- 270
- top: Breast Cancer
Recruiting share is below the 37% national average by 2 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
New York vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
10,554 Top 6% more indexed trials than 94% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for New York on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
New York open-enrollment share sits below the national baseline.
3,675 of 10,554 in-state trials (34.8%) are recruiting, against 37% nationally (-2.2 percentage points). Counts include every study with at least one recorded site in the state.
-
New York dominates New York's trial geography.
New York lists 7,184 of 10,554 in-state trials (68.1%) across 2,359 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Breast Cancer is the most-studied condition in New York.
270 of 10,554 in-state trials (2.6%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.
-
New York sponsorship is fragmented across many organizations.
Memorial Sloan Kettering Cancer Center appears on 953 of 10,554 in-state trials (9%). Sponsor identity is as filed on ClinicalTrials.gov.
-
4,547 New York trials carry a completed status.
4,547 of 10,554 (43.1%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 4,547 |
| Recruiting | 3,675 |
| Active | 2,332 |
By Phase
| Phase | Trial count |
|---|---|
| NA | 2,649 |
| Phase 2 | 2,430 |
| Phase 1 | 1,944 |
| Phase 3 | 1,424 |
| Phase 4 | 445 |
| Early Phase 1 | 97 |
Top Conditions
Top Sponsors
Where trials run in New York
New York carries 7,184 of New York's 10,554 indexed trials (68%) across 2,359 named sites, ahead of Rochester at 907. 8 cities clear five listed trials, together naming 3,550 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| New York | 7,184 | 2,359 |
| Rochester | 907 | 288 |
| The Bronx | 846 | 315 |
| Buffalo | 750 | 228 |
| Commack | 557 | 108 |
| Harrison | 520 | 38 |
| Uniondale | 345 | 27 |
| Brooklyn | 289 | 187 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Volume high
New York indexes 10,554 in-state trials (p96 by registry volume among 52 states with sites).
New York: in-state trial volume sits in the high tercile
Geography is concentrated: New York alone accounts for 68% of New York's indexed trials (7,184 of 10,554), with Rochester a distant second at 907.
Phase mix: 1,424 Phase 3 vs 2,430 Phase 2 (early-phase heavy).
Top condition: Breast Cancer (270 trials); top sponsor Memorial Sloan Kettering Cancer Center (953).
high-volume · high-open figures (10,554 trials · 35% open) describe registry geography under the volume high read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near New York on in-state trial volume
Cross-state peers under the volume high read (high-volume · high-open), not the same-state browse list.
Similar high-volume hubs (± open share)
- Florida · 10,986 trials · 33% recruiting
- Texas · 9,951 trials · 37% recruiting
- Massachusetts · 7,667 trials · 35% recruiting
- Pennsylvania · 6,946 trials · 34% recruiting
- Illinois · 6,854 trials · 33% recruiting
Similar high-open peers (± trial volume)
- South Carolina · 35% recruiting · 1,706 trials
- Michigan · 34% recruiting · 4,790 trials
- Ohio · 35% recruiting · 6,514 trials
- Wyoming · 35% recruiting · 17 trials
- Oklahoma · 34% recruiting · 1,061 trials